A short trial conducted in 2013 and consisting of administering a drug to the ARSACS transgenic mice had some encouraging results. The mice improved their physical performance.
The second phase of this project will start in February 2014. This time, the drug will be given to the mice over a longer period and the impacts will be observed and analyzed.
The Foundation is contributing to the financing of this research experience.